

Glucagon-Like Peptide-1 Receptor Agonists Added to Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Historical Cohort Study Using the Diabetes Study From the Center of Tokyo Women's Medical University (DIACET)

メタデータ	言語: 出版者: 東京女子医科大学学会 公開日: 2024-01-12 キーワード (Ja): キーワード (En): 作成者: BABAZONO, Tetsuya, MURATA, Hidekazu, SATO, Manaka, TAKEUCHI, Masakazu メールアドレス: 所属:
URL	http://hdl.handle.net/10470/0002000052

Supplementary Table 4. Body weight (kg) over 12 months after adding a glucagon-like peptide-1 receptor agonist to a sodium-glucose cotransporter 2 inhibitor.

Time		All (n = 80)	DPP-4i use subgroup		BMI subgroup			HbA1c subgroup			Insulin use subgroup	
			Non-DPP-4i use (n = 62)	DPP-4i use (n = 18)	<25 kg/m ² (n = 11)	25 to <30 kg/m ² (n = 31)	≥30 kg/m ² (n = 38)	<8% (n = 20)	8% to <10% (n = 45)	≥10% (n = 15)	Insulin users (n = 28)	Insulin non-users (n = 52)
Baseline	n	80	62	18	11	31	38	20	45	15	28	52
	Mean ± SD	85.4 ± 17.2	83.5 ± 16.2	92.0 ± 19.6	65.8 ± 5.1	77.0 ± 7.6	98.0 ± 15.6	85.1 ± 21.8	84.2 ± 16.7	89.5 ± 11.2	88.5 ± 17.3	83.7 ± 17.1
3 months	n	74	56	18	11	28	35	19	42	13	26	48
	Mean ± SD	84.9 ± 17.1	82.6 ± 15.7	92.1 ± 19.6	65.8 ± 6.7	77.1 ± 7.1	97.3 ± 15.7	84.7 ± 20.9	83.7 ± 17.0	89.4 ± 10.5	89.0 ± 16.9	82.8 ± 17.0
	P-value*	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.56	0.001
6 months	n	76	59	17	10	29	37	19	43	14	26	50
	Mean ± SD	84.9 ± 17.2	83.0 ± 16.0	91.5 ± 20.0	65.1 ± 6.6	76.1 ± 7.3	97.1 ± 15.4	84.2 ± 21.3	83.7 ± 17.0	89.6 ± 10.4	88.8 ± 17.1	82.9 ± 17.0
	P-value*	1.0	1.0	1.0	1.0	0.98	1.0	1.0	1.0	1.0	0.57	<0.001
9 months	n	67	52	15	8	27	32	16	40	11	25	42
	Mean ± SD	84.3 ± 17.1	82.5 ± 16.1	90.6 ± 19.5	65.1 ± 8.0	75.4 ± 8.0	96.6 ± 15.4	84.9 ± 22.4	83.2 ± 16.6	87.4 ± 9.9	88.4 ± 17.5	81.9 ± 16.7
	P-value*	0.99	0.99	1.0	1.0	0.84	0.99	1.0	1.0	0.97	0.94	<0.001
12 months	n	67	51	16	8	26	33	14	40	13	23	44
	Mean ± SD	84.8 ± 16.9	82.9 ± 15.5	91.0 ± 19.8	64.4 ± 8.0	75.5 ± 7.0	97.1 ± 14.3	84.0 ± 20.8	83.6 ± 17.0	89.6 ± 10.9	91.2 ± 16.9	81.5 ± 16.0
	P-value*	1.0	1.0	1.0	0.98	0.88	1.0	1.0	1.0	1.0	0.95	0.001

*P-values are compared with baseline.

BMI, body mass index; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; SD, standard deviation; SGLT2i, sodium-glucose cotransporter 2 inhibitor.